Cover Image
Market Research Report
Product code
962264

Global Myasthenia Gravis Treatment Market 2020-2026

Published: | Orion Market Research Pvt Ltd | Delivery time: 2-3 business days

Price

Back to Top
Global Myasthenia Gravis Treatment Market 2020-2026
Published: July 30, 2020
Orion Market Research Pvt Ltd
Delivery time: 2-3 business days
  • ALL
  • Description
  • Table of Contents
Description

Global Myasthenia Gravis Treatment Market Size, Share & Trends Analysis Report by Treatment (Medication, Surgery, Others) by End-User (Hospitals, Clinics, Others) Forecast period (2020-2026)

The myasthenia gravis treatment market is anticipated to showcase a considerable growth rate during the forecast period. The high prevalence of myasthenia gravis along with high investment in R&D of drugs and equipment is a key factor contributing towards the growth of the global myasthenia gravis treatment market. However, patent loss of costly drugs is anticipated to restrain the growth of the global market.

The myasthenia gravis treatment market is segmented on the basis of treatment and end-user. Based on the treatment, the myasthenia gravis treatment market is segmented into medication, surgery, and others. Based on end-user, the market is segmented into hospitals, clinics, and others. Hospitals to hold major market share based on end-user. The presence of a large patient pool and the availability of advanced equipment in hospital settings is anticipated to contribute towards the high share of this market segment.

Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is anticipated to hold a considerable market share due to the high awareness of the drugs for the treatment of myasthenia gravis in the region. Asia-Pacific is the fastest-growing region in the myasthenia gravis treatment market. The increasing prevalence of the auto-immune disorder in the emerging economies of Asia-Pacific is a key factor contributing to the growth of the market in the region.

LEO Pharma A/S, Mylan N.V., Bausch Health Companies Inc., Bayer HealthCare AG, Encore Dermatology, Inc., Abbvie Inc., Allergan PLC, Bausch Health Companies Inc., Encore Dermatology Inc., GlaxoSmithKline PLC, Nestle SA, Novartis International AG, Pfizer Inc., and so on are the key companies operating in the market across the globe. The major players of the myasthenia gravis treatment market are making hefty investments in the R&D of new drugs. The continuous efforts of the market players in the development of new drugs are driving the growth of the global myasthenia gravis treatment market.

Research Methodology

The market study of the global myasthenia gravis treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Myasthenia Gravis Treatment Market Research and Analysis by Treatment

2. Global Myasthenia Gravis Treatment Market Research and Analysis by End-User

The Report Covers:

  • Comprehensive research methodology of the global myasthenia gravis treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global myasthenia gravis treatment market.
  • Insights about market determinants which are stimulating the global myasthenia gravis treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Table of Contents
Product Code: OMR2022166

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. By Stakeholders

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Competitive Dashboard
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Alexion Pharmaceutical Inc.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Novartis AG
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Grifols SA
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. F. Hoffmann-La Roche, Ltd.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. AbbVie, Inc.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.1. Opportunities

5. Market Segmentation

  • 5.1. Global Myasthenia Gravis Treatment Market by Treatment
    • 5.1.1. Medication
      • 5.1.1.1. Cholinesterase Inhibitors
      • 5.1.1.2. Corticosteroids
      • 5.1.1.3. Immunosuppressants
    • 5.1.2. Surgery
    • 5.1.3. Others
  • 5.2. Global Myasthenia Gravis Treatment Market by End-User
    • 5.2.1. Hospitals
    • 5.2.2. Clinics
    • 5.2.3. Other

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. US
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AbbVie, Inc.
  • 7.2. Alexion Pharmaceutical, Inc.
  • 7.3. Amneal Pharmaceuticals, Inc.
  • 7.4. Argenx SE
  • 7.5. Astellas Pharma, Inc.
  • 7.6. Avadel Pharmaceuticals PLC
  • 7.7. Bausch Health Companies Inc.
  • 7.8. Baxter International, Inc.
  • 7.9. CSL Behring
  • 7.10. CuraVac, Inc.
  • 7.11. F. Hoffmann-La Roche, Ltd.
  • 7.12. GlaxoSmithKline plc
  • 7.13. Grifols SA
  • 7.14. Immunovant, Inc.
  • 7.15. Mitsubishi Tanabe Pharma Corp.
  • 7.16. Novartis AG
  • 7.17. RA Pharmaceuticals, Inc.
  • 7.18. Takeda Pharmaceutical Co., Ltd.
  • 7.19. UCB Pharma
  • 7.20. Valeant Pharmaceuticals International, Inc.

LIST OF TABLES

  • 1. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 2. GLOBAL MEDICATION MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL SURGERY MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 6. GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 10. NORTH AMERICAN MYASTHENIA GRAVIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 11. NORTH AMERICAN MYASTHENIA GRAVIS TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 12. EUROPEAN MYASTHENIA GRAVIS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 13. EUROPEAN MYASTHENIA GRAVIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 14. EUROPEAN MYASTHENIA GRAVIS TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 15. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 16. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 17. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 18. REST OF THE WORLD MYASTHENIA GRAVIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 19. REST OF THE WORLD MYASTHENIA GRAVIS TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SHARE BY TREATMENT, 2019 VS 2026 (%)
  • 2. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SHARE BY END-USER, 2019 VS 2026 (%)
  • 3. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. THE US MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)

16. REST OF THE WORLD MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)